Psoriasis Clinical Trial
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
Summary
This is a multi-center, open-label extension (OLE) study in patients with plaque psoriasis who have completed their participation in a previous plaque psoriasis study of ESK-001.
Full Description
This study will consist of patients who have completed their participation in a previous plaque psoriasis study of ESK-001. Each patient will be assigned to receive ESK-001 at one of two open-label dose levels. Patients have the option to remain on study until ESK-001 is commercially available.
Eligibility Criteria
Inclusion Criteria:
Must have completed a prior ESK-001 study
Men and Women must use highly effective methods of contraception for the entirety of the study
Exclusion Criteria:
Pregnancy
Received a prohibited concomitant medication
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 36 Locations for this study
Birmingham Alabama, 35205, United States
Phoenix Arizona, 85032, United States
Rogers Arkansas, 72758, United States
Encinitas California, 92024, United States
Los Angeles California, 90045, United States
Santa Monica California, 90404, United States
Sherman Oaks California, 91403, United States
Fort Lauderdale Florida, 33308, United States
Hialeah Florida, 33012, United States
Miami Florida, 33175, United States
Tampa Florida, 33614, United States
Rolling Meadows Illinois, 60008, United States
Columbus Indiana, 47201, United States
South Bend Indiana, 46617, United States
Overland Park Kansas, 66210, United States
Owensboro Kentucky, 42301, United States
Clarkston Michigan, 48346, United States
New Brighton Minnesota, 55112, United States
Portsmouth New Hampshire, 03801, United States
Norman Oklahoma, 73071, United States
Portland Oregon, 97223, United States
Philadelphia Pennsylvania, 19103, United States
Rapid City South Dakota, 57702, United States
Houston Texas, 77056, United States
San Antonio Texas, 78213, United States
South Jordan Utah, 84095, United States
Edmonton Alberta, T6G 1, Canada
Surrey British Columbia, V3V 0, Canada
Winnipeg Manitoba, R3M 3, Canada
London Ontario, N6H 5, Canada
Mississauga Ontario, L4Y 4, Canada
North Bay Ontario, PiB 3, Canada
Oakville Ontario, L6J 7, Canada
Toronto Ontario, M3H 5, Canada
Waterloo Ontario, N2J 1, Canada
Quebec , G1V 4, Canada
How clear is this clinincal trial information?